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The cytokines lymphotoxin (LT) a, b and their receptor (LTbR) belong to the tumor necrosis factor (TNF) superfamily, whose founder-TNFa-was initially discovered due to its tumor necrotizing activity. LTbR signaling serves pleiotropic functions including the control of lymphoid organ development, support of efficient immune responses against pathogens due to maintenance of intact lymphoid structures, induction of tertiary lymphoid organs, liver regeneration or control of lipid homeostasis. Signaling through LTbR comprises the noncanonical/canonical nuclear factor-jB (NF-jB) pathways thus inducing chemokine, cytokine or adhesion molecule expression, cell proliferation and cell survival. Blocking LTbR signaling or Fcc-receptor mediated immunoablation of LT-expressing cells was demonstrated to be beneficial in various infectious or noninfectious inflammatory or autoimmune disorders. Only recently, LTbR signaling was shown to initiate inflammation-induced carcinogenesis, to influence primary tumorigenesis and to control reemergence of carcinoma in various cancer models through distinct mechanisms. Indeed, LTbR signaling inhibition has already been used as efficient anti-inflammatory, anti-cancer therapy in some experimental models. Here, we review the pleiotropic functions attributed to LT, the effects of its deregulation and extensively discuss the recent literature on LT's link to carcinogenesis. Oncogene (2010) 29, 5006-5018; doi:10.1038 /onc.2010 ; published online 5 July 2010
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Inflammation-induced carcinogenesis
In the last decade, several studies have corroborated the tight link between chronic inflammation and carcinogenesis. Consequently, the inflammatory microenvironment was added as the seventh hallmark of cancer (Hanahan and Weinberg, 2000; Colotta et al., 2009) . This was ultimately the result of more than 100 years of research-indeed-the first observation that tumors often arise at sites of inflammation was initially reported in the nineteenth century by Virchow (Balkwill and Mantovani, 2001) . Today, understanding the underlying mechanisms of why immune cells can be pro-or anticarcinogenic in different types of tumors and which cellular and molecular inflammatory mediators (for example, macrophages, lymphocytes, chemokines or cytokines) drive or potentially prevent carcinogenesis is subject of intense research (Supplementary material). Here, we focus on the cytokines lymphotoxin (LT) a and b and their involvement in inflammation-induced carcinogenesis.
LT, a molecule with a long history
In the 1960s and early 1970s, two molecules were described based on their ability to promote cell death in target cells (for example, L cells; fibroblasts) (Ruddle and Waksman, 1967; Granger and Williams, 1968) . In 1967, a 'cytotoxic factor' was described causing toxicity on fibroblasts in presence of specific antigens Waksman, 1967, 1968) . Further, in 1968, a cytotoxic molecule produced by lymphocytes was reported and named LT (Granger and Williams, 1968; Granger et al., 1969) . In 1975, a substance was depicted causing efficient necrosis in various tumor types in vivo throughout a cytotoxic activity and was thus denominated 'tumor necrosis factor' (TNF) (Carswell et al., 1975) . These molecules subsequently caught attention of several research groups using these cytotoxic, tumornecrotizing capabilities for their therapeutic potential in the treatment of human cancer. In 1984, human LT was the first cytokine to be purified from a b-lymphoblastoid cell line (Aggarwal et al., 1984) and thereafter its aminoacid sequence and structure were determined (Aggarwal et al., 1985a; Nedwin et al., 1985a) . Neutralization of LT activity by LT-specific antibodies led to the isolation of a second cytotoxic factor from a human myeloid cell line, already known as TNFa (Aggarwal et al., 1985b) . Amino-acid sequence determination revealed close relationship of TNF to LT, resulting in the renaming of LT into TNFb. It became evident that these two cytokines are prototypic members of a gene superfamily, later defined as the TNF superfamily (TNFSF) (Hehlgans and Pfeffer, 2005) . Interestingly, murine and human TNFa and b genes are close to each other within the major histocompatibility complex region (mouse, chromosome 17 (Nedospasov et al., 1986a, b) ; man, short arm of chromosome 6 (Nedwin et al., 1985b; Muller et al., 1987) ). Later a third ligand-homologous to TNFb-was identified within the major histocompatibility complex locus and named LTb (TNFSF3; (Hiserodt et al., 1977; Ware and Granger, 1979; Browning et al., 1993; Pokholok et al., 1995) , whereas subsequently TNFb was termed LTa or TNFSF1B. At present, 19 different ligands belong to the TNFSF, including, for example, TRAIL, RANKL, BAFF, CD40 (Aggarwal, 2003) , mediating their cellular response through 29 receptors, which contain an extracellular cysteine-rich domain (Aggarwal, 2003) and in some cases (for example, TNFR1, TNFR2, TRAIL R1, TRAIL R2, Fas) a death domain.
LT, LTbR and their cellular origin
Under physiological conditions, LT is expressed by T-, B-, natural killer (NK)-and lymphoid tissue-inducer cells . Although LTa mRNA expression is inducible in B-cells, LTb mRNA is constitutively produced (Browning et al., 1993; Worm and Geha, 1994) . LTb is exclusively anchored in the membrane as a type II transmembrane protein, binding LTa to form membrane-anchored heterotrimers (LTa 1 b 2 and LTa 2 b 1 ; Browning et al., 1993 Browning et al., , 1995 . LTab heterotrimers can also be cleaved from the cell surface by matrix metalloproteases eliciting responses on distal cells (Young et al., 2010) . In contrast to LTb, LTa can be secreted as a soluble LTa 3 homotrimer. LTa and TNF homotrimers bind and signal through the TNF receptors TNFR1 or TNFR2. LTa 1 b 2 triggers LTbR, whereas LTa 2 b 1 was reported to bind TNFR1 and TNFR2, but this is a diminutive LT form expressed by T-cells (o2%) with an undefined biological role (Ware, 2005) . LIGHT (TNFSF14) is an alternative ligand for the LTbR but also interacts with herpesvirus entry mediator (Schneider et al., 2004) . LTbR is mainly expressed on parenchymal and stromal cells-but apparently also on myeloid cells (Norris and Ware, 2007) . Its signaling might enable the communication between lymphocytes and stromal cells, thereby influencing various biological processes (Gommerman and Browning, 2003; Ware, 2005; Lo et al., 2007; Tumanov et al., 2009) .
LTbR activation and NF-jB signaling
LTa, LTb and LTbR, as other TNFSF members activate canonical/noncanonical nuclear factor-kB (NF-kB) signaling, a major regulator of innate and adaptive immune responses, cell survival or apoptosis, cellular stress responses, development and maintenance of lymphoid organs (Figure 1) .
Activation of the canonical NF-kB pathway mainly occurs in response to inflammatory cytokines such as TNF, and IL-1, engagement of the T-cell receptor and in response to bacterial infection (for example, lipopolysaccharide). Interestingly, LTbR activation (through LIGHT or LTab heterotrimers) can also activate the canonical NF-kB (Dejardin et al., 2002; Muller and Siebenlist, 2003; Haybaeck et al., 2009) .
In addition to the canonical pathway a parallel signaling cascade exists called noncanonical pathway of NF-kB activation. Stimulation of a subset of TNFR family members, such as LTbR and CD40, can activate the noncanonical NF-kB pathway (Coope et al., 2002; Pomerantz and Baltimore, 2002) . These stimuli appear to converge upon NF-kB-inducing kinase , which is required for IKKa phosphorylation (Ling et al., 1998) . In this pathway, IKKa is thought to exist as a homodimer, independent of NEMO/IKKg and IKKb (Senftleben et al., 2001) . Activated IKKa phosphorylates p100, thereby inducing its proteasomedependent processing to p52. The p52/RelB dimer then translocates into the nucleus to induce gene expression through NF-kB activation by the LTa 1 b 2 , LTbR, NF-kB-inducing kinase, IKKa pathway. This pathway is crucial for development and maintenance of spleen architecture, follicular dendritic cell maturation, lymph node, Peyer's patch and NALT organogenesis as well as regulation of B-cell survival (Weih and Caamano, 2003) . Studies with mutant mice showed a phenotypic overlap between LT or LTbR deficiencies and inactivated NFkB signaling (Bonizzi and Karin, 2004; . Some of these findings are currently challenged by recently published results in vitro (Britanova et al., 2008) . Thus, explanations for the noncanonical pathway specificity await further experiments. LTa
, LTb À/À and LTbR À/À mice display severe developmental defects in lymph node and Peyer's patch neogenesis, a disorganized lymphoid microarchitecture and lack of mature follicular dendritic cells (Pfeffer et al., 1993; De Togni et al., 1994; Koni et al., 1997; Futterer et al., 1998; Ngo et al., 1999) . In addition, LTa À/À and LTbR À/À mice show inflammatory disorders in nonlymphoid organs (for example, lung, liver, kidney; (Fu et al., 1997 (Fu et al., , 2000 Fu and Chaplin, 1999; Chin et al., 2003) . Whether these inflammatory disorders are due to decreased expression of the autoimmune regulator, a key mediator of central tolerance for peripherally restricted antigens, in LTa À/À , LTb À/À and LTbR À/À mice (Chin et al., 2003) is challenged by various publications (Boehm et al., 2003; Rossi et al., 2007) .
LT and inflammation
A major role of LT in inflammation was first implied by its ability to activate endothelial cells in vitro to express adhesion molecules (for example, V-CAM, I-CAM) (Pober, 1987; Pober et al., 1987; Cavender et al., 1989) , to regulate expression of homeostatic chemokines (for example, CXCL13, CCL19, CCL21) (Ansel et al., 2000; McCarthy et al., 2006) and to induce a variety of pro-and anti-inflammatory chemokines (for example, CCL5, CCL2, CXCL10) (Cuff et al., 1998 (Cuff et al., , 1999 .
The role of LT in the context of lymphoid neogenesis, development of autoimmune diseases and inflammatory disorders was further investigated in vivo (Picarella et al., 1992; Kratz et al., 1996; Luther et al., 2000; Drayton et al., 2003 Drayton et al., , 2006 Gommerman and Browning, 2003; Martin et al., 2004; Heikenwalder et al., 2005 Heikenwalder et al., , 2008 Haybaeck et al., 2009) . These studies revealed that ectopic LT expression suffices to generate lymphoid-like structures (Picarella et al., 1992; Kratz et al., 1996; Gommerman and Browning, 2003; Heikenwalder et al., 2005; Haybaeck et al., 2009) , also termed tertiary lymphoid organs or tissues. LTa or LTab expression under the control of the rat insulin promoter II (RIP) induces chemokine expression and follicular lymphocytic infiltrations with mature follicular dendritic cell networks, resulting in chronic insulitis and glomerulonephritis (Picarella et al., 1992; Kratz et al., 1996; Drayton et al., 2003) . Inflamed sites in RIPLTa or RIPLTab mice are vascularized with endothelia showing morphologic characteristics of high endothelial venules (Picarella et al., 1992; Cuff et al., 1999; Drayton et al., 2003) . Further, it has been reported that LTbR signaling is a requirement for the homeostatic control of high endothelial venule differentiation and function (Browning et al., 2005) . Overexpression of LTab under the liver-specific albumin promoter (AlbLTab) led to chronic hepatitis, organized portal and lobular lymphocytic infiltrates, follicular dendritic cells and germinal centers leading to mild, chronic liver damage ( This leads to the activation of the IKK complex by phosphorylation of NEMO/IKKg and IKKb, which results in the phosphorylation of IkBa, its subsequent ubiquitylation and proteasomal degradation. Finally, the heterodimeric p50-RelA complex translocates to the nucleus, where it binds to specific kB-sequences and induces the expression of target genes, including pro-inflammatory cytokines or genes involved in cell survival, cell proliferation and pro-carcinogenesis. (Right) The noncanonical pathway becomes activated by membrane-bound LTa 1 b 2 heterotrimers, which results in the activation of NF-kB-inducing kinase (NIK). This leads to the phosphorylation and activation of the homodimeric IKKa complex. As a consequence, the precursor p100 becomes phosphorylated and proteasomally processed to the p52 subunit establishing now the RelB-p52 heterodimeric complex that translocates to the nucleus and induces the expression of target genes. Besides, LTbR was shown to activate the canonical NF-kB signaling pathway.
Development of tertiary lymphoid organs is observed in multiple human infectious diseases, such as viral-induced chronic hepatitis (for example, hepatitis B virus (HBV), hepatitis C virus (HCV)) (Llovet et al., 2003) , Helicobacter pylori-driven gastritis (Genta et al., 1993; Kobayashi et al., 2004) or chronic lyme disease (Steere et al., 1988; Ghosh et al., 2005) . Moreover, tertiary lymphoid organs also frequently appear in autoimmune diseases such as Sjo¨gren's syndrome (Hjelmervik et al., 2005) , chronic obstructive pulmonary disease, rheumatoid arthritis (RA) (Young et al., 1984; Takemura et al., 2001) , Graves' disease (Armengol et al., 2003; Aust et al., 2004) or multiple sclerosis (Prineas 1979; Serafini et al., 2004) . In most of these diseases, elevated expression of LT or its target genes has been detected, supporting LT's role in lymphoid neogenesis (Drayton et al., 2006) . Suppression of LTbR signaling by injection of LTbR-Ig was efficacious in the treatment of various inflammatory or autoimmune disease models (Gommerman and Browning, 2003; Ware, 2005; Drayton et al., 2006; Browning, 2008; Haybaeck et al., 2009 ).
Depletion of LT hi expressing cells and curing autoimmune diseases
Pleiotropic functions are attributed to LT in both health and disease -which in some instances can go beyond the well-documented role of LT in the development and maintenance of lymphoid organs. This includes an important role of LT signaling in the acceptance of donor stem cells, controlling cuprizone-induced demyelination, the progression of experimental autoimmune encephalomyelitis and the control of lipid metabolism or liver regeneration Lo et al., 2007; Plant et al., 2007; Markey et al., 2009; Ruddell et al., 2009; Tumanov et al., 2009) . Studies with different mouse models revealed a role of LTbR signaling in atherosclerosis development (Schreyer et al., 2002; Grabner et al., 2009) and an involvement of LTbR signaling was discovered in the pathogenesis of RA (Fava et al., 2003) . Blocking LTbR signaling using a LTbR-Ig fusion protein could prevent the onset of collagen-induced arthritis or reduce its severity, depending on the time point of LTbR-Ig treatment (Fava et al., 2003) . On the basis of these results, clinical trials with patients suffering from RA have been initiated by Biogen Idec (Boston, MA, USA) to investigate the beneficial role of LTbR-Ig (Baminercept). Baminercept has been studied in both healthy volunteers and in several phase 2 trials in RA with patients who have incomplete responses to either disease-modifying anti-rheumatic drugs or TNF inhibitor therapy. The RA studies did not meet their end points for American College of Rheumatology (ACR) score improvement and other indications are now being pursued (Biogen Idec, unpublished data) .
Recently, targeted depletion of LTa hi T H 1 and T H 17 cells with a monoclonal antibody against LTa could inhibit autoimmune disease in mouse models for delayed-type hypersensitivity, experimental autoimmune encephalomyelitis and collagen-induced arthritis, reflecting a correlation between LTa hi T H 1 and T H 17 cells and disease progression in the respective models (Chiang et al., 2009 ).
LT and cancer
As if the biological functions of LT were not multifaceted enough, various studies have also suggested the involvement of LTbR signaling in cancer development. Of these reports, some have focused more on the integrity of LT at the genetic/genomic level and the association of polymorphisms in the human LTA gene with cancer, for example, as being predictive for the outcome of various cancer types. In the case of diffuse, large B-cell lymphoma, a polymorphism in the LTA gene, was described to be linked with faster rate of disease progression (Chae et al., 2010) . It remains elusive how instructive these genetic studies will be, because most LTA polymorphisms and their pathological consequences are not described in detail.
Other studies have focused on the activation of LTbR signaling pathways in various cancer types. Bergsagel and colleagues reported a constitutive activation of NF-kB signaling in multiple myeloma as a result of mutations in the LTbR gene (Keats et al., 2007) , emphasizing a critical role for the NF-kB pathway in its pathogenesis. Furthermore, constitutive NF-kB activity was detected in diffuse large B-cell lymphoma, indicating a role for this signaling pathway as a primary pathogenic event in lymphomagenesis (Compagno et al., 2009) .
In addition, LTbR-mediated signaling-most likely through the noncanonical NF-kB pathway-is also involved in tumor angiogenesis. Activation of LTbR on fibrosarcoma cells by activated host lymphocytes is capable of initiating a novel, pro-angiogenic pathway leading to organized tumor tissue development. Conversely, in this model, inhibition of LTbR signaling prevented tumor angiogenesis and neovascularization, resulting in tumor growth arrest (Hehlgans et al., 2002) .
Hepatic LTbR signaling and HCC
Chronic inflammation, NF-kB activation and signaling by members of the TNFSF have been shown to contribute to hepatocellular carcinoma (HCC) progression. This is substantiated by analysis of multidrug resistance gene 2 knockout (mdr2 À/À ) mice, which spontaneously develop cholestatic hepatitis, elevated hepatocyte proliferation and subsequently HCC (Pikarsky et al., 2004) .
In a model of chemically-induced carcinogenesis, the anticipated pro-tumorigenic role of canonical NF-kB signaling in hepatocytes was confounded by the finding that mice lacking IKKb only in hepatocytes exhibited a profound increase in hepatocarcinogenesis after diethlynitrosamine (DEN) application (Maeda et al., 2005; Maeda and Omata, 2008) . This was associated with augmented hepatocyte death, indicating that compensatory proliferation might be a crucial step in HCC development. However, the absence of IKKb in both hepatocytes and bone marrow-derived Kupffer cells decreased compensatory proliferation and carcinogenesis. This suggests that canonical NF-kB activation in Kupffer cells is essential for the promotion of compensatory hepatocyte proliferation resulting in DEN-induced HCC. Using a transplant system which allows initiated mouse hepatocytes to form HCC, He and colleagues studied late events of tumor progression and malignant conversion in the DEN model (He et al., 2010) . Deletion of IKKb long after tumor initiation accelerated HCC development in a cell-autonomous manner (He et al., 2010) . Furthermore, the absence of IKKb in hepatocytes was associated with STAT3 activation. Hepatocyte-specific ablation of STAT3 blocked HCC development, suggesting an interface between NF-kB and STAT3 signaling in the context of DEN-mediated HCC development.
Other members of the IKK complex were also shown to be crucially involved in the protection or promotion of HCC. Ablation of NEMO/IKKg in hepatocytes results in the development of steatohepatitis and HCC (Luedde et al., 2007) . In this model, spontaneous HCC development is preceded by steatohepatitis, increased hepatocyte apoptosis and compensatory liver regeneration. These findings suggest that NF-kB has an active role in protecting the liver from cancer and emphasizes the role of NEMO/IKKg as a tumor suppressor (Luedde et al., 2007) . Of note, it was described that the MAP3-kinase TGF-b-activated kinase 1 (TAK1) suppresses a NEMO-dependent but NF-kB-independent pathway to liver cancer (Bettermann et al., 2010) .
Recently, a causal involvement of LTbR signaling in chronic hepatitis and HCC was proposed. Patients suffering from HBV-or HCV-induced chronic hepatitis or HCC displayed increased hepatic expression of LTa, LTb and LTbR (Haybaeck et al., 2009 ). But which cell type is responsible for the elevated expression of LT in chronic HCV-infected patients? Under physiological conditions, LT is predominantly produced by lymphocytes. However, infection of Huh-7.5 cells with fully infectious, cell culture-derived HCV also leads to elevated levels of LTa, LTb, LIGHT and LTbR transcripts 48 and 72 h after infection. Therefore, LT expression in HCV-infected livers could stem from lymphocytes and hepatocytes. Cells were collected from curative resections of HCV-induced hepatitis and HCC specimens and sorted according to their CD45 surface expression, resulting in CD45-enriched (T-, Band NK-cells; monocytes, macrophages/Kupffer cells; dendritic and NK-cells) or CD45-depleted (hepatocytes, oval cells, bile duct epithelial and endothelial cells) fractions. CD45 þ cells showed elevated expression of LTa and LTb, both in HCV-induced hepatitis and HCC. However, also the CD45 À cell fraction showed an elevation in LTa, LTb and LTbR mRNA expression in liver tissues from HCV-induced hepatitis and HCC, which was corroborated by immunohistochemical analysis for LTb (Haybaeck et al., 2009 ).
To determine whether sustained hepatic LTbR signaling is causally linked to hepatitis and liver cancer development, we analyzed mice expressing LTa and b in a liver-specific manner (AlbLTab mice) (Haybaeck et al., 2009) . From 6 months onward transgenic mice developed hepatitis characterized by infiltrating B-, T-cells, macrophages, hepatocyte and oval cell proliferation. This caused mild liver damage documented by elevated serum transaminase (ALT/AST) levels and enhanced production of cytokines/chemokines such as IL6, IL1b, IFNg and CCL2. Chronic hepatitis incidence reached 100% in 9-month-old mice, with infiltrates increasing in size over time (Figure 2) . In approximately one-third of the mice at an age X12 months chronic inflammation caused the development of HCC. Tumors are characterized by the presence of Ki67 þ hepatocytes, expression of gp73 (GOLPH2), a-fetoprotein and glutamine synthetase (Figure 2 , Haybaeck et al., 2009) . Furthermore, array comparative genomic hybridization analysis revealed that HCC displayed chromosomal aberrations.
But is LT itself an oncogene causing HCC development and is hepatic activation of LTbR sufficient to cause inflammation-induced carcinogenesis? To address these questions, we crossed AlbLTab to various knockout mice. Intercrossings with TNFR1 À/À mice should answer whether the absence of TNFR1 signaling could prevent HCC formation. Moreover, the role of lymphocytes and NF-kB signaling in the development of inflammation-induced HCC formation was assessed by intercrossing AlbLTab mice to RAG1 À/À mice, which lack mature B-and T-cells, and to IKKb Dhep mice, devoid of canonical NF-kB signaling in hepatocytes. AlbLTab/ RAG1 À/À or AlbLTab/IKKb Dhep mice did not display chronic hepatitis or HCC, suggesting that lymphocytes and NF-kB signaling are tumor promoting. Further, this suggested that LT itself is not an oncogene but rather that its sustained hepatic expression creates a pro-carcinogenic environment. Intercrossing to TNFR1 À/À mice did not alter hepatitis or HCC incidence, suggesting that chronic hepatitis and HCC formation in AlbLTab mice does not depend on pathways involving TNFR1.
The major LT responsive liver cell type was identified by using IKKb Dhep mice. I.v. administration of TNF to IKKb Dhep mice did not cause p65 translocation in hepatocytes but upregulated NF-kB target genes, presumably through TNF-activated non-parenchymal cells (NPC). In contrast, treatment with an agonistic LTbR antibody (3C8) in IKKb Dhep mice neither induced nuclear p65 translocation in hepatocytes and NPC nor upregulation of selected NF-kB target genes. Therefore, hepatocytes but not NPC are likely to be the major cells integrating LT signaling in the liver. In addition, upon 3C8 treatment, IKKa AA/AA livers upregulated selected NF-kB target genes, similar to C57BL/6 mice. Thus, IKKa deficiency in both hepatocytes and NPC does not block NF-kB target gene expression upon 3C8 treatment, suggesting the involvement of the canonical NF-kB pathway in LTbR-induced hepatic signaling.
Treatment of 9-month-old AlbLTab mice with LTbR-Ig reduced the incidence of chronic hepatitis and chronic hepatitis-driven HCC formation compared to untreated mice, suggesting that suppression of LTbR signaling reduces chronic hepatitis incidence and subsequent transition towards HCC (Figure 3a) . This shows that LT signaling is critically involved in hepatitis and subsequent HCC development. Blocking LTbR signaling might become beneficial in liver diseases with sustained hepatic LTbR signaling. A clinical trial using baminercept as an anti-viral and anti-cancer drug is currently being initiated (Villanueva et al., 2009) and potential side effects of long-term blockade of LTbR signaling in humans (for example, effects on lymphoid tissue microarchitecture; NK-cell compartment) have already been and will continue to be investigated.
Agonistic LTbR activation and suppression of solid tumor growth
LTbR was shown to be expressed in several solid tumors, for example, colorectal, larynx/pharynx and lung tumors, as well as in melanomas (Lukashev et al., 2006) . Recently, Lukashev et al. (2006) have proposed a mechanism by which agonistic activation of the LTbR using a monoclonal antibody (mAb; CBE11) suppresses tumor growth and enhances tumor chemosensitivity. Using a syngeneic colon carcinoma tumor xenograft model (CT26), it was shown that treatment of tumor-bearing mice with a murine agonistic LTbR antibody (AC6H) caused increased lymphocyte infiltration and tumor necrosis. However, extensive studies revealed that there are human cell lines resistant to CBE11 treatment, indicating that treatment success may depend on the cancer cell type. Moreover, CBE11 treatment decreased tumor size and/or improved long-term animal survival in two out of six orthotopic xenografts derived from independent surgical colorectal carcinoma samples. Inhibition of tumor growth by CBE11 could possibly result from direct activation of LTbR on tumor endothelial cells proposing two potential effects: (1) Involvement of LTbR signaling in interacting with mechanisms that control cell survival and tumorigenesis (Rayet and Gelinas, 1999; Wang et al., 2002) .
(2) LTbR-induced tumor inhibition may involve modulation of cell-cycle progression, thereby contributing to the tumor chemosensitivity (Lukashev et al., 2006) . Further, LTbR activation may interfere with tumor progression through induction of host-mediated immunological responses, for example by the upregulation of pro-inflammatory and homeostatic cytokines attracting various anti-tumor immune cells. þ monocytes. Activated, infiltrating immune cells secrete cytotoxic cytokines (for example, IL6, IL1b, TNFa, IFNg, LTab) that cause tissue destruction, hepatocyte proliferation, cell death and tissue remodeling. In such an environment, hepatocytes are susceptible to chromosomal aberrations leading to HCC. Tissue destruction and remodeling supports the infiltration of activated inflammatory cells (for example, myeloid cells) leading to a feed-forward loop towards chronic aggressive hepatitis. Asterisks indicate that genetic depletion of those components (IKKb; T-and B-cells) blocks chronic hepatitis development and HCC. Blocking LTbR signaling with LTbR-Ig in 9-month-old AlbLTab mice reduces chronic hepatitis incidence and prevents HCC. þ , indicates the fortification of a described process; B, indicates the suppression of a described process. The transcription factor RelA is schematically depicted as a green circle, inducing transcription of NF-kB target genes (for example, chemokines) (arrow). B, T, B-and T-cells; MØ, macrophages; N, neutrophils; NK, NK-cells. Adapted from Haybaeck et al. (2009) . (b) Scheme summarizing in vivo studies showing the pro-and anti-tumorigenic effects of LTbR activation or inhibition as well as consequences of LTa deficiency on anti-tumor surveillance (colored sectors). Experiments describing the pro-or anti-carcinogenic effects (depicted with þ or À) of activated LTbR signaling in vivo (Hehlgans et al., 2002 (5) ; Lukashev et al., 2006 (6) ; Haybaeck et al., 2009 (1); Or et al., 2009 (3) ; Zhou et al., 2009 (4) ; Ammirante et al., 2010 (2) ). (Gray sector) The gray sector indicates that also lack of LTa signaling can influence anti-tumor surveillance causing significant enhancement of experimental pulmonary metastases upon injection of B16F10 melanoma (Ito et al., 1999 (7) ). (Right column) Depicts various studies indicating that block of LTbR signaling might work as an anti-tumor strategy. CaP, prostate cancer; CRCaP, castration resistant prostate cancer; FSC, fibrosarcoma; HCC, hepatocellular carcinoma; NPC, nasopharyngeal carcinoma.
Unexpected role of LTbR signaling in carcinogenesis
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LT and anti-tumor T-cells
In contrast, genetic or conditional blockade of LTbR signaling was recently shown to lead to an effective antitumor T-cell response (Zhou et al., 2009) . The researchers investigated a nonantigen-based cancer immune prevention strategy using the transgenic adenocarcinoma prostate mouse model (TRAMP) that expresses the SV40 T-antigen controlled by rat probasin regulatory elements. TRAMP mice spontaneously develop prostate cancer with 100% penetrance and metastases. LTa deficiency in TRAMP mice prevented efficient negative selection of tumor-reactive T-cells, reduced primary prostate cancer incidence by approximately 50%, significantly reduced the size of prostate cancers and almost completely ablated metastases. Similarly, treatment with LTbR-Ig interrupted clonal T-cell deletion, reduced the size of the primary cancer and completely prevented further metastasis, showing the value of nonantigen-based immune prevention for individuals with genetic predisposition to cancer (Zhou et al., 2009 ).
B-cell-derived LT controls reemergence of castrationresistant prostate cancer
A study by Ammirante et al. (2010) deals with progression of prostate cancer (CaP), mainly focusing on the mechanisms underlying the recurrence of castration-resistant (CR) metastatic carcinomas. In addition to the previously described TRAMP model, subcutaneous allografts of mouse androgen-dependent AD-CaP cell line myc-CaP, were used to facilitate better mechanistic analysis of CR-CaP development.
To determine whether inflammation-responsive IKKb participates in development of CR-CaP, Ammirante and colleagues deleted IKKb in prostate epithelial cells of TRAMP mice. This neither affected primary tumor growth nor CR-CaP emergence after castration (Ammirante et al., 2010) . In contrast, specific deletion of IKKb in bone marrow-derived cells delayed development of CR-CaP emergence, although lacking effects on primary tumor development. These results, suggested an involvement of immune cells promoting tumor emergence after castration. Indeed, after androgen ablation the regressing tumors were infiltrated with T-and B-cells, NK-cells and myeloid cell types. Furthermore, inflammatory cytokines, for example, IL-6, IL-12, TNFa and LT, were upregulated in the regressing myc-CaP allografts. Further, STAT3, an antiapoptotic and pro-tumorigenic transcription factor, was activated during CR-CaP emergence. Notably, LT ablation on B-cells, but not on T-cells delayed CRCaP growth. Accordingly, in addition to mediators released by dying CaP cells, critical participants in tumor emergence are tumor-infiltrating B-cells, producing LT that signals through LTbR on CaP cells to induce IKKa nuclear translocation and STAT3 activation. This enhances androgen-independent growth of CaP cells. Therefore, the inflammatory response elicited by the dying primary tumor contributes to the failure of current therapy. Interventions that prevent LT production or ablate LT signaling could delay regressing tumors in patients with androgen ablation therapy.
Involvement of LTbR signaling in head and neck cancer
In a study on nasopharyngeal carcinoma (NPC), a distinct type of head and neck cancer, LTbR was shown to be frequently overexpressed in primary NPC tumors, concomitant with an amplification of chromosome 12p13.3 . In vitro studies in nasopharyngeal epithelial cells revealed increased NF-kB activity and cell proliferation due to LTbR overexpression. Addition of LTa 1 b 2 led to increased proliferation of nasopharyngeal epithelial cells and siRNA knockdown of LTbR expression inhibited growth of the NPC tumors with 12p13.3 amplification , further strengthening a tumor-promoting role of LTbR signaling in this type of carcinoma.
Involvement of LTa signaling in anti-tumor surveillance
Interestingly, LTa signaling may also be involved in the maturation and recruitment of NK-cells and may have an important role in anti-tumor surveillance. Ito et al. (1999) have shown that LTa deficiency leads to defects in NK maturation and recruitment and that formation of experimental pulmonary metastases upon injection of B16F10 melanoma cells was enhanced in LTa À/À mice (Ito et al., 1999) . Therefore, LTa signaling may be involved in NK-cell maturation, recruitment and antitumor surveillance.
Of note, LT's involvement is very unlikely to be universal to all cancer types or signaling pathways contributing to or enabling carcinogenesis: In an illuminating study, Kuprash et al. (2008) showed that neither lack of TNF nor LTa reduced tumor burden on a p53-deficient background, suggesting that at least in the context of p53-deficiency LTa signaling does not aggravate carcinogenesis.
Summary
Recent reports convincingly show an involvement of LTbR signaling in inflammatory processes and carcinogenesis (Table 1 )-however, they may involve distinct mechanisms in the various in vivo paradigms tested so far. What could be the reason(s) why increased LTbR signaling generates in some instances a pro-carcinogenic (Haybaeck et al., 2009) and in others an anti-carcinogenic environment (Lukashev et al., 2006) ? Data by Lukashev et al. (2006) indicate that agonistic LTbR antibody treatment induces lymphocyte infiltration and tumor necrosis in a syngeneic colon tumor model. One proposed mechanism might be the induction of chemokine expression, functioning as chemoattractant for T-, NK-and dendritic cells, driving tumor destruction. Whether these results are applicable to other tumor types needs to be investigated. LTbR-Ig treatment or genetic depletion of LTa in TRAMP mice interrupted clonal T-cell deletion, reduced the size of the primary CaP and prevented further metastasis (Zhou et al., 2009) , suggesting a role of LT in controlling anti-tumor T-cell selection and primary cancer development. Moreover, depletion of LT expression on B-cells-and not on T-cellsdelayed CR-CaP recurrence (Ammirante et al., 2010) , pointing toward a therapeutic application of LTbR signaling inhibition even as a tool to fight cancer re-emergence.
In summary, there is a compelling case for potential roles of LTbR signaling in carcinogenesis. However, more is to be learned about the link between LT signaling and cancer: (1) at the site of carcinogenesis and (2) at the site where the host's adaptive immune response is triggered against cancer (Figure 3b ). Exciting times are ahead, verifying the utility of LTbR antagonists or agonists in the different clinical settings and hopefully revealing the detailed mechanisms of LTbR signaling in the context of inflammation and cancer.
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